首   页
所况介绍
科研团队
科研成果
美国药学学会-福州大学分会
人才招聘
通知系统
Lee Jia
发布日期:2014-05-06    浏览次数:
Lee Jia\
 
Distinguished Professor
Tel: 0591-83576912
E-mail: pharmlink@gmail.com
 
EDUCATION
Post-Doctoral Fellow, Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA, 1994-1996.
Ph.D. (Pharmacology), State University of New York, NY, USA: Mentor Dr. Robert F. Furchgott, the 1998 Nobel Laureate, 1990-1994.
M.S. (Pharmaceutical Science), China Pharmaceutical University, China,1984-1987.
B.S.  (Pharmacy), Fudan University, College of Pharmacy, China,1978-1982.
 
PROFESSIONAL AND ADMINISTRAINAL EXPERIENCE
Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talents plan); Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China. 01/2012-present.
Senior Pharmacologist; Senior Project Officer (Permanent Tenure, GS14/Step 9), Toxicology and Pharmacology Branch, Developmental Therapeutics Program (DTP), Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD, 04/2005-04/2012.
Senior Pharmacologist; Project Officer (Conditional Tenure,
GS14/Step 6), Developmental Therapeutics Program (DTP),
Division of Cancer Treatment & Diagnosis, National Cancer Institute/ NIH; Rockville, MD, 04/2002-2005
Visiting Professor, Chinese Academy of Science Key Laboratory for Biomedical Effects of Nanomaterials and Nano-safety, Beijing, China. 2008-Present.
Visiting Professor, Chinese Academy of Science Key Laboratory for Biomedical Effects of Nanomaterials and Nano-safety, Beijing, China. 2008-Present
Associate Director, Department of Translational Research; Head, PK/PD Laboratory. Institute for Drug Development/ Cancer Therapy & Research Center, San Antonio, TX, 02/2000-03/2002
Associate Member (equivalent to Associate Professor), San Antonio Cancer Institute, San Antonio, TX, 05/2000-03/2002
Group Leader and Member of IACUC (Institutional Animal Care and Use Committee), La Jolla Pharmaceutical Company, San Diego, CA, 1998-1999
Senior Researcher, Dept. of Medicine, Uni. California San Diego,
CA.  
Visiting Scholar, Chinese Academy of Medical Sciences, Beijing, China. 1996-1998
Post-doctor, NitroMed Inc. / Department of Medicine, Divisions of Respiratory & Cardiovascular Medicine, Duke University Medical Center, Durham, NC, 1994-1996.
PhD. Research supervised by Dr. Robert F. Furchgott, the 1998 Nobel Laureate, SUNY, NY. 1990-1994
Project Leader, Clinical Pharmacy and Pharmacology, East Hospital, China, 1987-1989.
 
Courses taught
 
l   Annual Graduate Teaching Course (IBS708- Modern Drug Design and Development) given to Summer Semester at University of Alabama at Birmingham, AL., USA, every year. “Basic Knowledge about Investigational New Drug (IND) Application: Processes, Data Integration and Package Preparations” (2008-2010)
 
l   Annual Graduate Teaching Course: Interdisciplinary knowledge and skills on new drug research and development (2012-present)
 
l   Annual Graduate Teaching Course: Pharmacokinetics (2012-present)
 
PROFESSIONAL MEMBERSHIPS, ACTIVITIES AND AWARDS
 
·   Member, American Association of Pharmaceutical Scientists (AAPS, 135447)
·   Committee, Fujian Pharmacological Society, China (2012-present)
·   Vice-Chair, Chair-elect, Chair and Past Chair (2009- present), AAPS Drug Design & Discovery Section (1800 members)
·   2012 AAPS Program Coordination Committee, Award Committee
·   2011 AAPS annual meeting programming committee
·   Chair-elected (2007-2009), and Chair (2009-2010), AAPS CRO Focus Group (600+ members)
·   AAPS Nanotechnology Focus Group Steering Committee
·   AAPS Fellow
·   Member, American Association for Cancer Research (AACR, 75164)
·   Member, American Heart Association (1997-2000)
·   Executive Board Member, State University of New York Alumni Association (2004- president)
·   2004 National Cancer Institute Merit Awards
·   1998 American Heart Society Travel  Award
·   Yangtze River (Changjiang) Scholar Honorable Professor (1999);
·   The Chinese 1000-talent Scheme Honorable Scholar (2011)
·   The Fujian Science & Technology Innovation Talent (2011). 
·   First-class Army Bioscience and Technology Research Award: S-nitrosohemoglobin,1997
·   Vice Chair, Graduate Student Association, China Pharmaceutical University (1985-1987)    
 
EDITORIAL SERVICES
 
Organize review processes for submitted manuscripts, including identifying and inviting qualified reviewers, analyzing reviewers’ critiques, comments, and overall scores to make final fair justifications, setting criteria for acceptance, rejection, and revision.   
 
1.              Associate Editor, Current Drug Metabolism (2005-present);
2.              Editorial Advisory Board Member, Current NanoSciences (2005-present);
3.              International Editorial Advisory Board, Therapeutic Delivery (2010-present);
4.              Editorial Board Member, Pharmaceutica Analytica Acta (2010-present)
5.              Editorial Board Member, Pharmaceutical Regulatory Affairs (OMICS Publishing Group; 2011-pesent)
6.              Editorial Board Member, International J. Tumor Therapy; Scientific & Academic Publishing (2011-Present)
7.              Associate Editor, Drug Metabolism Letter (2007-present);
8.              Editorial Advisory Board Member, Current Bioactive Compounds (2007-present);
9.              Editorial Board Member, The Open Drug Metabolism Journal (2008-present);
10.         Editorial Advisory Board Member, The Open Drug Delivery Journal (2008-present);
11.         《药物分析杂志》特邀编委(2012年--)
12.         《贵阳医学院学报》特邀编委(2013年--)
13.         Advisor to the Science and Technology Group Publishers (2008-present);
 
Invited     Reviewers for the Following 37 Journals:
 
1.     Cell Biology & Toxicology;
2.     J. Pharm. Sci;
3.     Brain Research;
4.     Biochem Pharmacol;
5.     Letters in Drug Design & Discovery;
6.     Rapid Communications in Mass Spectrometry;
7.     Biopharmaceutics & Drug Disposition;
8.     J. Pharm. BioMed. Anal;
9.     Clinica Chimica Acta;
10.         NeuroScience Letters;
11.         J. Pharmacol. Exp. Ther;
12.         Molecular Pharmacology;
13.         Anti-Cancer Agents in Medicinal Chemistry;
14.         Current Drug Metabolism;
15.         Bioorganic & Medicinal Chemistry Letters;
16.         Biomedical Chromatography;
17.         J. Chromatography;
18.         Planta Medica;
19.         Xenobiotics;
20.         Molecular Pharmaceutics;
21.         Acta Pharmacol Sin.;
22.         Drug Metabolism Letter;
23.         Curr. NanoScience;
24.         Arch Pharmacol.;
25.         Drug Metabolism and Disposition (ASPET);
26.         Toxicology Letter;
27.         Biomaterials
28.         Chinese Medicine
29.         Current HIV Research
30.         J. NanoSci. NanoTech.
31.         Therapeutic Delivery
32.         Journal of Medicinal Plant Research
33.         Drug Discovery Today
34.         Biomaterials
35.         Current Medicinal Chemistry
36.         Toxicological Sciences
37.         Journal of Acquired Immune Deficiency Syndromes (JAIDS)
38.         The AAPS J
 
Peer-reviewer invited by the Medical Research Council (MRC) of South Africa (a statutory science council that is responsible for managing and funding research in South Africa) to evaluate the merit of research proposals submitted for funding.
 
Abstracts Reviewer for Annual AAPS Conferences.
 
Invited Speaker, Conference MODerate and ORGANIZER, teaching
 
1.        Presentation entitled “Discovery of nitric oxide/ EDRF and its pharmacological effects” in East Hospital, Fuzhou, China, June, 1997.
 
2.        Invited speaker, “S-nitrosylation and related drug discovery and development”, Nov. 1997, in Shenyang PHARON Health Products Co. LTD.
 
3.        Invited speaker, presentation title “L-Arginine increases GFR partially by nitric oxide independent mechanism via activity of agmatine”.1998 American Society of Nephrology Annual Conference, Philadelphia, Oct. 25, 1998.
 
4.        Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” State University of New York at Buffalo, Nov., 2001. 
 
5.        Speaker, presentation title “EDRF Activity, Anticancer Spectrum and Pharmacokinetics of JS-K” NCI-SAIC Frederick, MD. Oct. 18, 2002.
 
6.        Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” Johnson & Johnson Pharmaceuticals, San Diego, CA. Feb. 2002. 
 
7.        Speaker, presentation title ‘Stability of JS-K in Biomatrices’ at NCI-SAIC Frederick, MD. Oct. 16, 2003.
 
8.        Speaker, presentation title ‘Public-private partnerships for development of 2nd generation of ethambutol analogs for tuberculosis treatment’. Sequella, Inc. Rockville, MD, Dec. 2, 2003.
 
9.        Invited speaker, presentation title “Nitric Oxide Research: From Hypothesis to Drug Development” in Division of Applied Pharmacology Research, OTR/OPS/CDER/FDA, April, 2004. 
 
10.   Speaker, presentation title ‘Interspecies pharmacokinetics of SQ109 and its metabolism profile’ Sequella, Inc. Rockville, MD. Aug. 3, 2004.
 
11.   Speaker, presentation title “In vitro and in vivo testing of JSK”. NCI-Frederick, MD 10/26/2006
 
12.   Speaker, Moderator and Organizer, presentation title “GLP-Regulations and Inspections in USA and China: Differences, Similarities and Case Analysis” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007, co-sponsored by Fudan University (SPFDU) and AAPS.
 
13.   Speaker, Moderator and Organizer, presentation title “New Drug Applications in USA and China: Acceptability, Data Requirements and Benefit/Risk Analyses” in the two-day conference “Pharmaceutical Outsourcing: Regulations, IP, Technology, Capabilities, and Partnership” Shanghai, China, April 2-4, 2007. I designed topics and agenda, invited prominent experts for presentations.
 
14.   Moderator and Organizer of the symposium entitled “Exploratory IND (phase 0 trial) and its practices” at the 2007 annual National Biotechnology Conference. San Diego, CA June, 26. 2007. I designed topics and agenda, invited leaders from the FDA, NIH, and Pharmaceutics who drafted or implemented the Phase 0 trials for presentations.
 
15.   Speaker, presented “Differences and similarities between USA and China in new drug application procedures and regulations”. Global R&D Congress, May 29-30, 2008, in Washington, DC,
 
16.   Moderator: 2008 AAPS, November 19, 2008. Georgia World Congress Center, Atlanta, Georgia, USA. “Outsourcing Drug Product Development to India and China” (Roundtable).
 
17.   Session Chair and Speaker, presented ‘Sino-USA collaboration: challenges and opportunities for advancing nanomedicine’, moderated a brainstorm panel session at The 1st Joint US-China Symposium on Nanobiology and NanoMedicine, Oct. 21-23, 2008; Fragrant Hill, Beijing, China;
 
18.   Moderator and Speaker: “Celebrating the Nanotechnology R&D Act: Then, Now and the Future” (Symposium), 2008 AAPS, November, 20, 2008. Georgia World Congress Center, Atlanta, Georgia, USA.
 
19.   Interviewed by Pharmaceutical Technology’s Live Vidcast, Nov. 18, 2008, on “Nanotechnology in Pharmaceutical Applications”. http://pharmtech.findpharma.com/pharmtech/cathome/catHome15.jsp?pid=1cMFmQS467AFBmTscDEbAdYP_ddYrr6Q
 
20.   Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the School of Pharmacy, Fujian Medical University, April 2, 2009.
 
21.   Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize In Medicine─Maximize Your Research Achievements By Publications And Networking” to the Nanobiological Center of Shanghai University, April 6, 2009.
 
22.   Invited speaker: “Differences and similarities in GLP-regulations and inspections between USA and China”, presented at Medicilon, Inc. April, 7. 2009.
 
23.   Invited Speaker: “Comparison of new drug application procedures and regulations between USA and China” at “China 2009 Pharmaceutical R&D Summit” 4th International Conference & Exhibition, April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China.
 
24.   Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements by Publications and Networking” to the School of Pharmacy Fudan University, April 9, 2009.
 
25.   Invited Speaker: “From Hypothesis to Discovery: Untold Stories about the 1998 Nobel Prize in Medicine─Maximize Your Research Achievements By Publications And Networking” to the China Pharmaceutical University, April 10, 2009.
 
26.   Seminar entitled “The Four-decade War on Cancer: Are We Winning???” presented to South China Center for Innovative Pharmaceuticals, Nov. 18, 2009.
 
27.   Speaker, presentation title “Anti-HIV drug development involved in ADME and nanotechnology”, and moderator at International Symposium of NanoMedicine on AIDS/HIV sponsored by Beijing University of Technology, the National Center for Nanosciences and Technology of China, AAPS, Chinese Academy of Sciences and Chinese Ministry of Science and Technology (MOST), Beijing, China; Nov.19-20, 2009.
 
28.   “Why we are not winning the war on cancer and how to lead the war to win: my view, my dreams and my strategies” presented at Graduate School of Pharmacy, Shanghai Jiao Tong University. Nov. 20. 2009.
 
29.   Invited Speaker, “Contemporary understanding of the Millennium Phytomedicine― Ginseng” in Symposium: The Appalachian Center for Ethnobotanical Studies (ACES) in Tai Sophia Institute in Laurel, MD, on Saturday 26 June 2010.
 
30.   Invited Speaker, “The four-decade war on cancer: are we winning?” in Capital Medical University, Beijing, China. 10/25/2010, afternoon 
 
31.   Invited Speaker, “The four-decade war on cancer: are we winning?” in Symposium 6: Advances of Drug Discover against cancers, The 8th Annual Congress of International Drug Discovery Science and Technology. 10/26/2010, 9:45-10:10 am 
 
32.   Invited Speaker, “Current understanding of cancer metastasis requires changes in strategies of anticancer drug development”, in symposium 5 of annual Chinese Pharmaceutical Association Conference; Beijing, China, 11/7/2010, 9:15-9:35 am
 
33.   Symposium: “Re-Engineering Nanomaterials with Biomolecules: Strategies, In Vivo Stability and Specificity, and Drugability", as both the moderator and speaker for the 2011 National Biotechnology Conference, Wednesday, May 18, 2011, from 1:30 pm - 4:00 pm, at the Hilton San Francisco, CA.
 
34.   Invited Speaker, “From understanding the complex of cancer metastasis to designing cancer nanomedicine: what nanomedicines can and can’t succeed” and moderator of Nano-pharmaceutics Session at the International conference of 2011 China Nano, at the National Convention Center, Beijing. Sept.7-9, 2011.
 
35.   Designed and Chaired the Hot topic: “The heating-up of pharmaceutical globalization:  current mergers and acquisitions by Chinese Pharma in the USA and basic knowledge of laws about drug importation to China”. October 24, 2011 12:15 PM – 1:30 PM, at the Walter E. Washington Convention Center, Washington, DC. USA (attendees 500)
 
36.   Session Chair, Symposium: “Global Competition and Geopolitical Priorities for Bionanotechnology R&D”. 9:00-11:00 am, Oct 25, 2011. Convention Center, Washington DC, USA. The 2011 AAPS.
 
37.   Speaker, Jia: “The market and contemporary understanding of the millennium phytomedicine-ginseng” and Session Chair “Evaluating Drug Development Opportunities in Botanical Polymolecular Therapeutics”. Time: Wed. 8:30-11:00 am, 10/26/2011; Place: Washington DC convention CTR.
 
38.   Speaker, Jia: “Overview of Global Development of Photodynamic Therapy for Cancer and   China’s First Generation of Photosensitizer ZnPcS2P2” and co-Chaired the session “Nanobiotechnology” with Dr. Chen Wang, Director, National CTR for Nanoscience & Technology; 19:20-22:00, Oct. 31, 2011. 17th International Biophysics Congress, Beijing.
 
39.   Invited speaker “Contemporary understanding of the nutraceutical ginseng: its anti-diabetic and cancer preventive effects and possible interaction with Warfarin”, and Session Chair “2012 International Conference on Ginseng”, Jilin, Chair; Sept. 4-7, 2012. (260 Attendees)
 
40.      Invited speaker “The 40-year war on cancer: are we winning or Losing, and our strategies” at Fujian Pharmacological Society Conference (150 attendees), Fuzhou, Nov. 17th, 2012. 福建药理学会报告和会议主持.
 
41.      Invited speaker “Re-engineering PAMAM dendrimer for its multivalent binding to colon cancer cells HT29” 第449次北京香山科学会议、即第3次中美癌症纳米技术和纳米医学研讨会(2012年12月5-7日)
 
42.      Invited speaker “Restrain activity of circulating tumor cells: the new strategy for preventing cancer from metastasis” at the China-US translational medicine international forum (250 attendees), 中国科协15届年会;Guiyan medical university, May 25, 2013.
 
43.      Invited speaker “The new strategy to prevent cancer from metastasis: restrain circulating tumor cells” at the 2013 AAPS@ China Symposium, the Chinese University of Hong Kong, August 17-18, 2013.
 
 
PRE-IND Packages and Meetings with FDA and IND APPLICATIONS
 
1.        Pyrrolobenzodiazepine (SJG-136), Preclinical pharmacology summary prepared by Jia. (Date filed: July 14, 2004; FDA IND# 70218; FDA approved August 13, 2004)
 
2.        Pre-IND packages and meetings with FDA and Sponsors: LIV-1, a novel drug delivery system to deliver 5-FU to hepatocytes and hepatoma cells to treat hepatocellular carcinoma (HCC). Cell-Works, Inc. Feb, 2003.
 
3.        R(-)Gossypol (AT-101), FDA IND# 68255: Pharmacology Summary prepared partially by Jia; Sponsor: Ascenta Therapeutics, 2005.
 
4.        SQ109, FDA IND# 69597: Pharmacology Summary prepared by Jia; Sponsor: Sequella, Inc. Filed in Sept. 2006.
 
5.        MV-NIS virus, a live tissue culture adapted measles virus selectively targeting human myeloma cells. FDA IND# 13023. May 3rd, 2006.
 
6.        Batracylin (NSC 320846): Pharmacology and Toxicology Summary prepared by Jia for IND filing; IND# 76254; Sponsor: National Cancer Institute. Completed in March, 2006.
 
7.        1-methyl-[D]-tryptophan (NSC721782; IND#78060): Pharmacology and Toxicology Summary prepared by Jia for IND filing; Sponsors: NCI and NewLink Co. Completed Aug., 2006. IND meeting: July 19, 2007.
 
8.        P-28 peptide (IND# 77754) Pre-IND meeting with FDA July, 12, 2007; IND submitted July 8, 2008.
 
9.        Development of allopregnanolone in Neiman-Pick type C disease (NP-C) PIND-74900 for treatment of inherited mitochondrial respiratory chain diseases; Pre-IND on Oct 17, 2006; White oak, Building 22/FDA; Sponsor: Edison Pharm.
 
10.   Pre-IND meeting with FDA for single chain urokinase plasminogen activator (ScuPA) (PIND 106014) development; Oct. 27, 2009.
 
11.   Pre-IND meeting with FDA for SPINALON designed to prevent or reverse chronic immobility-related health problems typically found in spinal cord-injured patients; Jan. 14, 2010.
 
12.   Pre-IND meeting with FDA for development of PEG-hemoglobin-based oxygen carriers (HBOC) for AfterShock treatment; Feb., 23, 2010, at FDA Woodmont Office Building, Rockville, MD.
 
PATENTS
 
1.      Jia, L.: Method of synthesis of S-nitrosocaptopril crystals and the use thereof (issued as both the inventor and owner: CO7D207/16).
 
2.      Jia, L. Garza, M, Wong, H, Redelmeier, T.E.: Intravenous carbendazim compositions (filed as inventor).
 
3.      Jia, L: Method and compounds that prevent circulating tumor cells from adhesion and extravasations to distant organs (filed as the inventor and owner: file # 201110338508.9)
 
4.      Jia, L.: Medicinal combination that prevent cancer metastasis after surgical removal of primary tumors (filed as the inventor and owner: file # 201210379714.9)
PUBLICATIONS
 
1.       Jia, L*. Chemistry, pharmacology, toxicity and clinical uses of Tripterygium Wilfordii.    J.  Chinese  Pharmaceutical  20: 101-106, 1985
              
2.       Jia, L*. Studies on physicochemical stability of triptolide injection.  J. Chinese  Pharmaceutical  20: 629, 1985.                    
 
3        Jia, L* Probit analysis of LD50 of triptolide and its cytotoxicity.  Chinese J. Pharmacol Toxical.  1: 78-80, 1986.
 
4.       Jia, L* Studies on angiotensin converting enzyme inhibitors. Prog. Physiol. Sci. 6:229-234, 1985.        
 
5.       Jia, L* Hoe, D. H.: Negative chronotropic effects of meglumine cyclic adenylate on cardiac pacemaker in vitro and in vivo.  Acta  Pharmacol  Sin   9: 421-426, 1988.
 
6.                 Jia, L*, Hoe, D. H.: Antiarrhythmic effects of meglumine cyclic adenylate. Chinese J. Pharmacol. Toxical.  3: 251-255,1989.
 
7.       Jia, L*,  Hoe, D. H.: Effects of meglumine cyclic adenylate on contractility, oxygen consumption and excitability of Langendorff heart and cardiac cells.  Chinese J. Pharmacol. Toxicol. 2:16-19,1988.
 
8.       Jia, L*. Hoe, D. H.: Effects of meglumine cyclic adenylate on drug-induced positive chronotropic action in rabbit right atria.  Chinese J. Pharmacol  Toxicol.  2: 235-238, 1988.
 
9       Jia, L.: Adenosine Receptors and adenosine pharmacology.    Chinese  Pharmacol.  Bull. 5: 129-133, 1989.
 
11.     Jia, L and Furchgott R.F.: Inhibition by sulfhydryl compounds of vascular  relaxation induced by nitric oxide and endothelium-derived relaxing factor  J. Pharmacol. Exp. Ther. 267:371-378, 1993   
 
12.     Jia, L* Liu, X., Furchgott R. F.:  Blockade of nitric oxide-induced relaxation of rabbit aorta by cysteine and homocysteine. Acta.  Pharmacol.  Sin. 18(1):11-20, 1997.          
 
13.     Jia L, Bonaventura, C., Bonaventura, J. and Stamler, J. S.: S-nitrosohemoglobin:  a dynamic activity of blood involved in vascular control.     Nature    380: 221-226, 1996                
 
14.     Simon, D.I., Mullins, M.E., Jia, L., Gaston, B., Singel, D. J., Stamler, J.S.: Polynitrosylated Proteins: Characterization, bioactivity and functional consequences.  Proc. Natl. Acad. Sci. U.S.A.  93: 4736-4741, 1996.
 
15.    Day, B J, Jia L, Arnelle DR, Crapo, JD, and Stamler, JS.: Transduction of  NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In  Biology of NO, ed. by Moncada, Stamler, Gross and Higgs, pp. 202-4  Portland Press, London, 1996.
 
16.     Jia, L* Clinical trials and therapeutic implications of nitric oxide and its donors.  Pharmaceutical Commun Sin. (Review).     13: (3) 204-206, 1997, 
 
17.     Stamler, J.S., Jia, L., Eu, J.P., McMahon, T.J., Demchenko, I.T., Bonaventura, J., Piantadosi, C.A.: Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient.    Science. 276: 2034-2037, 1997.
 
18.     Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L*.    Inhibitory effects of S-nitrosocaptopril on vasomotor tone.  Acta Pharmacol  Sin.    1998, 19 (5): 485-488.
 
19.     Jia, L* and Stamler, J. S.: Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier.  Eur.  J.  Pharmacol   1999, 366: 79-96.
 
20.     Lin, M, Yang X, Wang, J., Jia, B.J., Jia, L. S-nitrosocaptopril preferentially decreases diastolic pressure in hypertensive models. Chinese Pharm. Bulletin  1999, 15(1) 73-76. 
 
21.     Jia,L*., Blantz, RC. The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats  Eur  J. Pharmacol. 1998, 354: 33-41.
 
22.     Jia, L*. Young, X, Guo, W:  Physicochemistry, pharmacokinetics and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor    J.  Pharm.  Sci.  1999, 88: 981-986.
 
23      Jia, L* A design of a novel compound S-nitrosocaptopril possessing the capacities of both angiotensin converting enzyme inhibitors and nitric oxide donors. Prog. Physiol. Sci. 1999, 29: 12-15.
 
24.     Jia, L* Nitric oxide research and new drugs: Challenges and success. Commentary on the 1998 Nobel Prize in Medicine.   Science (in Chinese) 1999, 51(2): 49-52.
 
25.    Lin, M., Jia, L*. International principles of nomenclature and abbreviations of nitric oxide research. Prog. Physiol. Sci. 1999, 30(4): 376-78.
 
 26.   Jia, L*, Yu, L. Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for the inhibition of xenotransplantation rejection.   J. Pharm. Pharmacol. 53: 999-1005, 2001.
 
27.   Jia, L*. Wu, C. Young, X: Anti-angiogenetic effects of S-nitrosocaptopril crystals as a    nitric oxide donor.  Eur.  J.  Pharmacol.  391: 137-144, 2000.
 
28.   Jia, L*. Pei, R. Lin, M. Young, X. Acute and subacute toxicity and efficacy of S-   nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.  Food &    Chem.      Toxicol. 39: 1135-1143, 2001.
 
29    Jia, L*. Garza, M. Wong, H. Camden, J. Redelmeier, T. Weitman, S. Pharmacokinetic    comparison of intravenous carbendazim and remote loaded carbendazim liposomes in    nude mice.  J. Pharm. Biomed Anal. 28(1): 65-72, 2002.
 
30.            Wong, H. Jia, L*. Camden, J. Weitman, S. Liquid chromatography-mass spectrometry assay of a thiodiazole derivative in mice: application to pharmacokinetic studies.  J. Chromatogr. 765:55-62, 2001.
 
31.            Jia, L*. Wong, H. In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor. Br. J. Pharmacol. 134: 1697-1704, 2001
 
32.            Jia, L*. Wong, H. Cerna, C. Weitman, S. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by LC/MS. Pharm. Res. 19:1091-1096, 2002.
 
33.            Jia, L*. Wong, H. Wang, Y. Garza, M. Weitman, S.    Carbendazim: Disposition, cellular permeability, metabolite identification and pharmacokinetic comparison with its nanoparticle. J. Pharm. Sci. 92:161-172, 2003.
 
34.            Jia, L*. Schweizer, J. Cerna, C. Wong, H. Revilla, M. Effect of Nitric Oxide on Cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem Pharmacol. 66:2193-2199, 2003.
 
35.            Jia, L*. Tomaszewski, J.E., Noker, P.E., Gorman, G.S., Glaze, E., Protopopova,M. Simultaneous determination of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J. Pharm. Biomed Anal. 37(2), 23-33, 2005.
 
36.            Jia, L*. Tomaszewski,J., Hanrahan, C. Coward, L. Noker, P. Gorman, L. Nikonenko, B. Protopopova, M. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144, 80-87, 2005.
 
37.            Jia, L*. Coward, L. Gorman, L. Noker, P. Tomaszewski, J. Pharmacoproteomic effects of isoniazid, ethambutol, and N-Geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.  J. Pharmacol. Exp. Ther. 315, 905-911, 2005.
 
38.            Saavedra, J.E., Srinivasan, A., Buzard, G.S., Davies, K.M., Waterhouse, D., Inami, K., Wilde, T.C., Citro, L.M., Cuellar, M., Deschamps, J.R., Parrish, D. Shami, P.J., Findlay, V.J. Jia, L., Ji, X., Keefer, L.K., PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.  J. Med. Chem49, 1157-1164, 2006.
 
39.            Jia, L*. Global governmental investment in nanotechnologies. Curr. NanoScience (Review) 1:(3) 263-266, 2005.
 
40.            Jia, L*. Nanoparticle formulation Increases oral bioavailability of poorly soluble drugs: experimental evidences, theory, and approaches. Curr. NanoScience (Review) 1:(3) 237-243, 2005.
 
41.            Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Pellecchia, M., Reed, J.C., Jia, L*. Quantitative determination of Apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J. Pharm. Biomed. Anal. 42: 581-586, 2006.
 
42.            Jia, L.*, Noker, P.E., Coward, L. Gorman, G. Protopopova, M., Tomaszewski, J.E. Interspecies pharmacokinetics and in vitro metabolism of SQ109   Br. J. Pharmacol. 147(5):476-85, 2006.
 
43.            Buhrow, S.A., Reid, J.M., Jia, L., Covey, J., Kobs, D.J., Grossi, I. M., Ames, M.M. LC/MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).  J. Chromatogr.  2006; 840: 56-62.
 
44.            Shami, PJ., Saavedra, J. E., Bonifant, C. L., Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo.  J. Med. Chem. 2006; 49(14); 4356-4366.
 
45.            Jia, L. Pharmaceutical Globalization: First International CRO/CMO Conference sponsored by the AAPS in China.  AAPS NewsMagazine 7(3): 67, 2007.
 
46.            Jia, L*, Wang, Y., Zhu, YZ.  Pharmaceutical globalization urges cooperation between China and USA on GLP regulations. Chinese Medicine & Drugs Newspaper, March 22, 2007
 
47.            Jia, L*., Zhu, Y., Wang, Y., Wu, W., Dong, Y.C., Zhang, R., Fu, L., Bi, H., Tam, J. Harmonising GLP rules in the US and China: The globalisation of the pharma industry means China and the US need bilateral agreements on GLP regulations. The Regulatory Affairs Journal  18(3):147-152, 2007.
 
48.            Liu, X.D., Jia*, L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab.  8: 815-821, 2007.
 
49.            Jia, L*., Liu, X.D. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr. Drug Metab.  8: 822-829, 2007.
 
50.            Jia, L.*, Schweikart, K., Tomaszewski, J., Reed, J., Ames, M, Page, J., Noker, P., Munn, D. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: absence of toxicity due to saturating absorption.   Food Chem. Toxicol. 46: 203-211, 2008.
51.            Jia, L.* Coward, L.C. Kerstner-Wood, Gorman, G., Noker, Kitada S, Pellecchia M P., Reed, J.C., Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.  Cancer Chemotherapy Pharmacol. 61: 63-73, 2008.
 
52.            Liu, H.Y., Liu, X.D., Jia, L., Liu, Y.C., Yang, H.W., Wang, G.J., Xie, L.  Insulin therapy restores impaired function and expression of P-glycoprotein in blood–brain barrier of experimental diabetes.  Biochem. Pharmacol. 75: 1649-1658, 2008.
 
53.            Jia*, L., Noker, P.E., Piazza, G.A., Leuschner, C., Hansel, W., Gorman, G.S., Coward, L.U., Tomaszewski, J. Pharmacokinetics and Pharmacodynamics of Phor21-βCG(ala), a lytic peptide conjugate. J. Pharm. Pharmacol. 60:1441-48, 2008.
 
54.            Liang, X.J., Chen, C.Y., Zhao, Y.L., Jia, L., Wang, P.C. Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials.  Curr. Drug Metab. 9(8): 697-709, 2008.
 
55.            Jia, L*. Drug discovery and development operations in emerging regions: global R&D congress. Thomson-Pharma, June, 2008 (invited conference proceedings)
 
56.            Song, M., Wang, L., Hang, T., Wen, A., Yang, L., Jia, L. Rapid and sensitive liquid chromatography-tandem mass spectrometry for rasagiline: assay development, validation and application to a human pharmacokinetic study.  J. Chromatogr. 875:515-521, 2008.
 
57.            Jia, L. The Great Meeting Held in the Bitter Cold Economic Climate: 2008 AAPS Annual Meeting and Exposition. Thomson-Pharma, December, 2008 (invited conference proceedings)
 
58.            Kitada, S., Kress, C.L., Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C. Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy with less toxicity compared to Gossypol (NSC19048).  Blood, 2008; 111: 3211 - 3219.
 
59.            Zhang, TT., Song, M., Hang, HJ., Xu, XF., Wen, A.D.,Yang, L., Jia, L*. Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J. Clin. Pharm. Ther.  33, 1-10, 2009.
 
60.            Jia* L. Zhao, YQ. Current Evaluation of Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations. Curr. Med. Chem. 16: 2475-2484, 2009.
 
61.            Jia*, L, Zhao, YQ. Liang, X.J. Current Evaluation of the Millennium Phytomedicine― Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine.  Curr. Med. Chem. 16: 2924-2942, 2009.
 
62.            Ni. L., Yu, X.,Yu, Q.,Chen, X., Jia, L*. Effects of cyclosporine A and itraconazole on permeability, biliary excretion and pharmacokinetics of amlodipine.  Drug Metab. Lett. 2(3): 163-168, 2008.
 
63.            Meng, J., Wang, D.L., Wang, P.C., Jia, L., Chen, C., Liang, XJ. Biomedical Activities of Endohedral Metallofullerene Optimized for Nanopharmaceutics. J. NanoSci NanoTech., 10: 8610-7, 2010.
 
64.            Jia*, L. Soldati, F. Ginseng, Asian (Panax ginseng); In Encyclopedia of Dietary Supplements. Ed by Coates PM. 2nd edition, pp.352-366, 2010; Informa Healthcare, New York, London. (invited review).
 
65.            Jia* L, Gu Y., Zeng E, Linnik, MD, Jones, DS. Biostability, Tissue Distribution and Disposition of LJP 993, a Tetrameric Conjugate of Domain 1 of b2-glycoprotein I for antiphospholipid syndrome. Lupus. 19: 130-137, 2010.
 
66.            Kiziltepe, T., Anderson, K.C., Kutok, J.L., Jia, L., Saavedra, J.E., Keefer, L.K., Shami, P.J. JS-K has potent anti-angiogenic activity in vitro and inhibits tumor angiogenesis in a multiple myeloma model in vivo. J. Pharm. Pharmacol 62: 145-151, 2010.
 
67.            Liang, XJ., Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P., Zhao, YL., Gao, X., Sun, B., Chen, CY., Xing, GM., Shen, DW., Yin, JJ., Gottesman M., Jia, L.  Metallofullerene Nanoparticles Overcome Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc. Natl. Acad. Sci. U.S.A. 107: 7449-7454, 2010.
 
68.            Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L, Liang, X.J. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discovery Today  15: 186-197; 2010.
 
69.            Ma, X.W., Wang, D.L., Wu. Y., Ho, R.J.Y., Jia, L., Guo, P., Hu, L., Xing, G.M., Zeng, Y., Liang, X.J., AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. The AAPS Journal 12, 272-278, 2010.
 
70.            Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., *Jia, L. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice J. Pharm. BioMed. Anal. 53: 991-996, 2010.
 
71.            Wang, YZ., Ma, XW., Ma, HL, Wang DL., Lu, J., Jia, L., Duan, XL., Liang, XJ. Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: altered iron metabolism and its implication as an acute hemosiderin model. Curr. Drug Metabo. 11, 507-515, 2010.
 
72.            Tang, W., Jia, L., Zhao, Y. The newly-found bioactivities and clinical uses of ginseng and ginsenosides. Ginseng Res. 22(2): 32-38, 2010.
 
73.            *Jia, L. Qian K. An Evidence-based Perspective of Ginseng as a Preventing or Supplementary Therapy for Cancer Patients. In Evidence-based Anticancer Herbal Medicine., Ed., by W. Cho, Springer Science. 85-95, 2011.
 
74.            Jia, L*, Zhao, YL, Liang, XJ. Fast Evolving Nanotechnology and Relevant Programs and Entities in China. Nano Today 6: 6-11, 2011.
 
75.            Reid, J.M., Buhrow, S.A., Kuffel, M.J., Jia, L.  Spanswick, V.J., Thurston, D.E., Tomaszewski, J.E., Ames, M.M. Pharmacokinetics, Pharmacodynamics and Metabolism of the Dimeric Pyrrolobenzodiazepine SJG-136 in Rats. Cancer Chemother. Pharmacol. 68: 777-786, 2011.
 
76.            Jia, L., Gorman, G., Coward, L., Noker, P., McCormick, D.L., Horn, H.L., Harder, J.B., Muzzio, M., Prabhakar, B., Balaji, G., Gupta, T.K.D., Beattie, C.W. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination Cancer Chemother. Pharmacol. 68: 513-24, 2011.
 
77.            徐哲;贾力;赵余庆。人参的词源学、生药学、产品及市场的现代评价 《现代药物与临床》2011年第02期 1-6
 
78.            XU, J. JIA, L., ZHAO, YQ Constituents of ginseng and quality evaluation of ginseng products.  Drug evaluation Research 2011; 34(3),1-5.
 
79.            Song M., Zhang, S., Xu, X., Hang, T., Jia, L. Simultaneous determination of three Panax notoginseng saponins by LC-MS/MS at sub-nanograms in dog plasma for pharmacokinetics of compound Danshen Tablets. J. Chromatogr. 878: 3331-7, 2010.
 
80.            Rayburn, E., Wang, W., Li, M., Zhang, X., Xu, H., Li, H., Qin, JJ., Jia, L., Covey, J., Lee, M., Zhang, R. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother. Pharmacol. 69:1423-31; 2012.
 
81.            Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, JM., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A.J., Kinders, R., Wang, L., Parchment, R.E., Carter, J., Stotler, H., Rubinstein, L., Hollingshead, M., Melillo, G., Pommier, Y., Bonner, W., Tomaszewski, JE., Doroshow, JH. Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res. 71:5626-34; 2011.
 
82.            Meng, J., Yang, X.D., Jia. L., Liang, X.J., Wang, C. Impact of nanoparticles on cardiovascular diseases: modulating metabolism and function of endothelial cells. Curr. Drug Metab. 13: 1123-29; 2012. IF5.113
 
83.            Jia, X., Jia, L*. Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy. Curr. Drug Metab. 13: 1119-22, 2012. IF5.113
 
84.            Xue, X., You, S., Zhang, Q., Wu, Y., Zou, GZ., Wang, PC., Zhao, YL., Xu, Y., Jia, L.,  Zhang, X., Liang, XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing
mitochondrial dysfunction. Mol. Pharmaceutics 9:634−644 ;2012. IF4.782
 
85.            Shao, J., Xue, JP., Dai, YC., Liu, H, Jia*, L, Chen, NS., Huang, JL. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 48: 2086-96; 2012. ISSN:0959-8049; IF5.536
 
86.            Meng, J., Xing, J., Wang, Y., Lu, Y., Zhao, YL., Gao, X., Wang, P.C., Jia, L. Liang, XJ. Epigenetic modulation of human breast cancer by metallofullerene nanoparticles: in vitro analysis and in vivo treatment. Nanoscale. 3: 4713-19; 2011. IF5.914
 
87.            Zhang, F., Xie, JP., Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein Binding
Data and Guidance for Study Designs. Drug Discovery Today 17:475-495,2012. IF6.828
 
88.            Jia, L.* Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech. 31:99-107, 2013. IF9.11
 
89.            Reid, JM., Buhrow, SA., Gilbert, JA., Jia, L., Shoji, M., Snyder, J., Ames. MM. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-Piperidione,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993) Cancer Chemother. Pharmacol. CCP-13-0564: Accepable Pending Revisions, 2014.
 
90.            Xu, Y., Jia, L. Nanoscaled Proteomic Analysis. 64-81, Chapter 4th In Nanopharmaceuticals Ed by Liang. World Scientific Publishing, Singapore. 2012.
 
91.            Shao, JW., Dai, Y., Zou, WT., Xue, JP., Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 330:49-56,2013. IF4.2
 
92.            Xie, JJ., Shao, JW., Lu, Y., Chen, JZ., Wang, J., Yu SH., Jia, L*. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr. Drug Metabo. 14:614-621;2013.
 
93.            Jiang, Z., Shao, J., Chen, M, Hu, Y., Wang, J., Jia*, L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst 138: 4385 – 4392, 2013. IF4.2
 
94.            Jia*, L. Science Requires Coexisting of Opposite Opinions: “One Country, Two Systems” Pharmaceutical Reg. Affairs: Open Access ISSN:2167-7689; 1(4):1000e114;2012
 
95.            Shao, J., Jia*, L. Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke. Trends Pharmacol. Sci. 34(2):85-86, 2013. IF10.927
 
96.            Yin, J.J., Sharma, S., Shumyak, S.P., Wang, Z.X., Zhou, Z., Zhang, Y., Guo, P., Li, C.Z., Kanwar, J.R., Yang, T.X., Mohapatra, S.S., Liu, W., Duan, W., Wang, J., Li, Q., Zhang, X., Tan, J., Jia, L. Liang, J., Wei, M.Q., Li, X., Zhou, S.F. Synthesis and Biological Evaluation of a Novel Cancer Treatment Based on Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE 8(5): e62289; 2013.
 
97.            Gao, Y. Xie, J., Chen, H., Gu, S., Zhao, R., Shao, J., Jia*, L. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotech Adv. 10.1016/j.biotechadv.2013.10.013. 
 
98.            Jiang, Z., Shao, J., Ting, Y., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 78:98-104; 2014.
 
99.            Gao, Y., Shao, J., Jiang, Z., Chen, J., Gu, S., Yu, S., Zheng, K., Jia, L.* Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Disc. Today  19:326-340,2014.
 
100.       Wang, J., Jiang, Z., Shao*, J., Ou, M., Li, Y., Lu, Y., Xiang, L., Lin, L., Dai, Y., Jia, L*, Synergism of ursolic acid derivative with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual targeting of apoptosis and glycolysis. Sci Reports 2014. (accepted)
 
101.       Chen, JZ., Wang, JC., Shao, JW., Gao, Y., Xu, JG, Yu, SH., Liu, ZH., Jia, L*. The Unique Pharmacological Characteristics of Mifepristone: from Terminating Pregnancy to Preventing Cancer Metastasis. Med. Res. Rev. 2014 (DOI 10.1002/med.21311)
 
102.       Wang, J., Chen, J., Wan, L., Shao, JW., Lu, Y., Zhu, Y., Ou, M., Yu, SH., Chen, HJ., Jia*, L. Synthesis, spectral characterization and pharmacological evaluation of metapristone, a novel cancer metastatic chemopreventive derived from mifepristone (RU486). AAPS J. 16:289-298,2014.
 
103.       Yu, S., Yang, X., Xie, F., Shao, J., Zhu, Y., Gao, Y., Mo, F., Jia, L.* Systems biological pharmacology of mifepristone (RU486) reveals its 57 potential targets for cancer chemotherapy and metastasis chemoprevention. Curr. Cancer Target Drugs 2014 (submitted)
 
104.       Chen, JZ, Wang, JC, Zeng, R, Gao, Y, Xu, J, Zhu, YW, Shao, JW., Jia,* L. A novel and rapid UPLC/MS/MS method and its application to pharmacokinetic determination of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486. J Pharm. Biomed. Anal, 2014  Doi 10.1016/j.jpba.2014.02.026 .
 
105.       Shao, JW., Gao, Y, Wang, JC., Chen, JZ., Yu, SH., Jiang, Z., Jia,*L. Three decades of transdisciplinary understanding and re-evaluating of the politics- and religion-involved abortion pill mifepristone and its niche in cancer metastasis chemoprevention. CA A Cancer J. 2013 (submitted)
 
106.       Lu, Y., Yu, T., Liang, H., Wang, J., Xie, J., Shao, J., Gao, Y., Yu, S., Chen, S., Wang, L., Jia, L.* Nitric oxide inhibits hetero-adhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initial metastatic cascade.  Scientific reports DOI: 10.1038/srep04344,2014
 
107.       Xie, JJ., Shao, JW., Zhao, R., Sinko, PJ., Gao, Y., Gu, S., Wang, J., Li, Y., Lu, Y.,  Yu, S., Jia*, L. Enhanced sensitivity and specificity of capturing and restraining circulating tumour cells in blood with dual antibody-coated nanomaterials. ACS. Nano. (submitted) 2014.
 
108.       Xie, JJ, Zhao, R, Songen Gu, Haiyan Dong, Jichuang Wang, Yusheng Lu, Ting Yu, Fangwei Xie, Lie Wang,Jingwei, Shao, Jia, L* The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention. Biomaterials (submitted) 2014
 
*, principal or corresponding author
 
ABSTRACTS
 
1.                 Jia, L: Pharmacokinetic differentiation of six substituted phenylethylamines.   Chinese Pharmaceutics Press pp. 16, 1988.
 
2.       Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new transport function of arterial erythrocytes involved in regulation of blood pressure.    Endothelium S6, 1995
 
3.      Day, B. J, L, Jia, Arnelle D. R, Crapo, J. D, and Stamler, J. S.: Transduction of NOS activity from endothelium to vascular smooth muscle: involvement of S-nitrosothiols  In Biology of Nitric Oxide.  Endothelium. S 72, 1995.   
 
4.                 Day, B. J, Jia, L, Crapo, J. D. and Stamler, J. S.:  EDRF and mechanisms of nitric oxide protection..        Am. J. Respir. Crit. Care  Med.    A 627, 1995.
 
5.       Jia L, Bonaventura C, Bonaventura J, Stamler JS: S-nitrosohemoglobin: a new synthetic activity of the lung involved in regulation of blood pressure.  Am.  J.  Respir.  Crit.  Med.  A 582, 1996.
 
6.       Zhang, J., Saman, G., Jia, L., Stamler, J.S., Cobb, F.R.:  Effects of S-nitrosohemoglobin on the conductance and resistance coronary vasculature.    Circulation, 94:(Suppl 1-16), 1996.
 
7.       Jia, L., Blantz, RC.  The effects of S-nitrosocaptopril on renal function and blood pressure in rats.   J. Am. Society   Nephrology.  8:317A, 1997.
 
8.       Jia, L. Zhang, J.: Pharmacokinetics of S-nitrosohemoglobin in unanethetized dogs   J.  Artificial Cells, Blood  Substitutes, Immobilization  Biotechnology  21, 1997   
 
9.                 Jia, L.: S-nitrosocaptopril crystals: physicochemical characterization and cardiovascular activities.  Am. J. Hypertension.  1998; 11(4): 105A. 
 
10.     Jia, L: Simultaneous measurement of pharmacodynamics and pharmacokinetics of S-nitrosocaptopril in hypertensive rats.  AAPS Western Regional Meeting  1998; page.41.                        
 
11.     Jia, L. Thomson, S. Blantz, R.  L-arginine increases GFR partially by nitric oxide independent mechanisms via activity of agmatine.    J.  Am. Society  Nephrology  1998; 308A.
 
12.            Jia, L.: VIPGC-NO preserves intrinsic function of VIP but acquires NO-like activities.  Am. J. Hypertension. 1999;12(4): 54A. 
 
13.            Lin, M., Yang, X, Wang.,  Jia, BJ., Jia, L.  S-nitrosocaptopril crystals preferentially decreases diastolic pressure in hypertensive rats.  Am. J. Hypertension.  1999; 12(4):114.
 
14.            Jia, L. Linnik, D.M.  The Stability of the first domain of b2-glycoprotein I in rat serum and microsomes.  AAPS PharmSci. 1999; 1(S1): 524.
 
15.            Jia, L., Yu, l., Linnik, D.M., Jack, R.M.  Stability and Pharmacokinetics of LJP 920, an octameric Gal (a1-3) Gal conjugate for inhibition of xenotransplantation rejection.    AAPS PharmSci. 1999; 1(S1): 11
 
16.            Jia, L., Pei, R. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities. AAPS PharmSci. 2000; 2(S1):726.
 
17.            Jia, L. Wong, H. Garza, M. Weitman, S. Pharmacokinetic Comparison of intravenous carbendazim and its liposome and emulsion forms in nude mice. Proc. Am. Assoc. Cancer Res. 42: 381, 2001.
 
18.            Jia, L. Garza, M. Wong, H. Wang, Y. Weitman, S. Paclitaxel Tumor cellular Permeability: Influence of plasma binding, P-glycoprotein and nitric oxide. Proc. Am. Assoc. Cancer Res. 42: 951, 2001.
 
19.            Wang, Y., Wong, H., Weitman, S. Jia, L. LC/MS/MS assay of a novel anti-virus drug 301029: application to cellular permeability studies. AAPS PharmSci. 2001; 3(S1): 861.
 
20.            Wong, H. Wang, Y. Weitman, S. Jia, L. Carcinoma cell permeability, tissue distribution and disposition of carbendazim, a novel anti-cancer drug.  Proc. Am. Assoc. Cancer Res. 43: 430, 2002.
 
21.            Wang, Y. Wong, H. Jia, L. Effect of S-nitrosocaptopril on Taxol permeability and cytotoxicity against carcinoma cells. Proc. Am. Assoc. Cancer Res. 43: 431, 2002. 
 
22.            Wong, H., Wang, Y., Garza, M. Weitman, S. Jia, L.  Carbendazim and its nanoparticle formulation: Pharmacokinetic comparison and metabolite identification.  AAPS PharmSci. 2001; 3(S1): 609.
 
23.            Wang, Y. Jia, L. Wong, H. Endothelial permeability to captopril and S-nitrosocaptopril and in vivo bioactivity thereof. AAPS PharmSci. 2001; 3(S1): 493.
 
24.            Jia, L. Wong, H. Cerna, C. Piazza, G. LC/MS/MS-based proteomic analysis of the membrane proteins of human prostate carcinoma LNCaP Cells. Proc. Am. Assoc. Cancer Res. 43: 34, 2002.
 
25.            Cerna, C. Wang, Y. Schweizer, J. Revilla, M. Wong, H. Jia, L. Effects of S-nitrosocaptopril on cytotoxicity and permeability of paclitaxel in human carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 43: 585, 2002.
 
26.            Jia, L. Wong, H. Cerna, C. Weitman, SD. Size-dependent absorption of micro- and nanoparticle 301029: ex vivo and in vivo pharmacokinetic correlations determined by LC/MS.  AAPS PharmSci. 2002; 4(S1): 1569.
 
27.            Jia, L. Tomaszewski, J. Jothianandan, D. Furchgott, R.F. Keefer, L. Shami, P. EDRF-like activity and anticancer spectrum of JS-K, a novel diazeniumdiolate nitric oxide donor.  Proc. Am. Assoc. Cancer Res. 44: 1059, 2003.
 
28.            Bolterman, S.A., Reid, J.M., Jia, L. Shami, P.J., Ames, M.M.  HPLC analysis of the NO-donating prodrug JS-K: inhibition of sulfhydryl-catalyzed degradation in plasma and whole blood lysates by thiol depletion with diamide. Proc. Am. Assoc. Cancer Res. 44: 387, 2003.
 
29.            Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol Analogs. I. LC/MS/MS analysis and cassette dosing for pharmacokinetic screening of candidate drugs. AAPS PharmSci. 2003; 5(S1): 716.
 
30.            Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. II. Pharmacokinetic characterization of SQ109. AAPS PharmSci. 2003; 5(S1): 724.
 
31.            Jia, L., Tomaszewski, J., Noker, P., Norman, G., Protopopova, M. Ethambutol analogs. Assessment of pharmacokinetic drug-drug interaction after cassette dosing. AAPS PharmSci. 2003; 5(S1): 719.
 
32.            Jia, L., Tomaszewski, J., Noker, P., Norman, G., Yang, D. Pharmacokinetic profiling of (-)Gossypol (NSC 726190), a novel anticancer agent. Molecular Targets & Cancer Ther. p241, 2003  (AACR-NCI-EORTC international conference).
 
33.            Reid, J., Buhrow, S.A., Kuffel, M., Jia, L., Covey, J., Ames, M.M. LC-MS/MS assay and rat pharmacokinetics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136. Proc. Am. Assoc. Cancer Res. 45:1248, 2004.
 
34.            Jia, L., Spanswick, VJ., Reid, JM., Kuffel, M. Buhrow, SA., Ames, MM., Hartley, JA., Thurston, DE., Tomaszewski, JE. Use of the Comet assay as a surrogate biomarker for the in vivo measurement of DNA damage to Lymphocytes. Proc. Am. Assoc. Cancer Res. 45: 452, 2004.
 
35.            Jia, L. Peggins, J., Reid, JM., Buhrow, SA., Ames, MM., Kobs, DJ., Grossi, IM., Thurston, DE., Tomaszewski, JE. Interspecies differences in pharmacokinetcs and time-dissociated toxicokinetics of SJG-136. Proc. Am. Assoc. Cancer Res. 45:487 2004.
 
36.            Coward, L, Cook, L. Kerstner-Wood, C. Noker, P. Page, J. Jia, L. Schweikart, K. Gorman, G. Simultaneous Determination of a Novel Synthetic Triterpenoid Derivative(CDDO-Im) and its Metabolites using LC/MS/MS. American Society of Mass Spectrometry(ASMS). May, 2004.
 
37.            Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. In vitro metabolic profiling of SQ109 and identification of main CYP isoforms catalyzing the metabolism. The AAPS Journal. 2004; 6(S1): 969.
 
38.            Jia, L. Noker, P.E. Gorman, G. Coward, L. Protopopova, M. Tomaszewski, J.E. Interspecies similarities and differences in pharmacokinetics of SQ109 (NSC722041), an anti-tuberculosis drug. The AAPS Journal. 2004; 6(S1): 1092.
 
39.            Shami, P.J., Kaur, G., Jia, L., Saavedra, J.E., Keefer, L.K. JS-K, a novel nitric oxide (NO) generator, shows potent anti-angiogenic activity.  Am. Society Hematology. Dec. 2004.  
 
40.            Glaze, E., Chen, Y., Lyubimov, A., Jia, L., Noker, P., Morrissey, R., Tomaszewski, J. Range-finding toxicity studies with SQ109, an anti-tuberculosis agent, in rats and dogs. 2005 Annual Society of Toxicology Conference.
 
41.            Jia, L., Coward, L., Gorman, G. Noker, P.E., Hanrahan, C., Protopopova, M. Tomaszewski, J.E.  Fingerprinting of pharmacoproteomic changes of mycobacterium tuberculosis H37Rv induced by anti-tuberculosis drugs.  2005 Annual Am. Thoracic Soc. San Diego, May.
 
42.            Jia, L., Gorman, G.S., Noker, P.E., Coward, L., Tomaszewski, J.E. In Vitro Metabolism Analysis of CDDO-Imidazolide. Proc. Am. Assoc. Cancer Res. 46: 779, 2005.
 
43.            Jia, L., Kuffel, M.J., Buhrow,S.A., Reid, J.M., Ames, M.M. Pharmacokinetic profile 1-methyl-[d]-tryptophan, an orally-bioavailable immune modulator.  Proc. Am. Assoc. Cancer Res. 46: 987, 2005.
 
44.            Coward, L.C. Kerstner-Wood, Noker, P., Gorman, G., Becattini, B., Pellecchia, M., Reed, J.C., Jia, L. Analysis of bioconversion from apogossypol hexaacetate to apogossypol, a novel proapoptotic compound. Proc. Am. Assoc. Cancer Res. 46: 530, 2005.
 
45.            Noker, P.E., Gorman, G.S., Coward, L., Hansel, W., Jia. L. Lytic Peptide Phor21-bCG(ala) I: Pharmacokinetic Profile in Mice and Rats. Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
46.            Piazza, G., Jones, Noker, P.E., Hansel, W., Leuschner, C., Jia, L. Lytic Peptide Phor21-βCG(ala) II: Selective Cytotoxicity and Its Effects on Membrane Integrity as Measured by Permeability to Mannitol. Proc. Am. Assoc. Cancer Res. 46: 1395, 2005.
 
47.            Kuffel, M.J., Buhrow, S.A., Reid, J.M., Jia, L., Ames, M.M. Kynurenine: a biomarker for in vitro and in vivo modulation of indoleamine 2,3-dioxygenase by 1-Methyl-[d]-tryptophan (NSC 721782)   Proc. Am. Assoc. Cancer Res. 46: 982, 2005.
 
48.            Sarah A. Buhrow, Joel M. Reid, Lee Jia, Mamoru Shoji, James P. Snyder, Dennis C. Liotta, Matthew M.  LC/MS/MS assay and mouse pharmacokinetics and metabolism of the novel curcumin analog EF-24 (NSC 716993).  Proc. Am. Assoc. Cancer Res. 46: 984, 2005.
 
49.            Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C.  Quantitative determination of formulation and biomatrix stability of Apogossypol, a novel proapoptotic compound. The AAPS Journal 7(S2): T2307; 2005.
 
50.            Jia, L., Noker, P., Coward, L., Gorman, G., Reed, J.C. In vitro and in vivo bioconversion of apogossypol hexaacetate to apogossypol: implication for chemotherapy development.  Clin. Cancer Res. 11(24 Suppl):9072s, 2005.
 
51.            Jia, L. Tomaszewski, J. Toxicokinetic profile of Batracylin in beagle dogs. The Toxicologist 90(1):122, 2006. (Abstract # 596)
 
52.            Kuffel, MJ., Buhrow, SA., Myers, RM., Greiner, SM., Harvey, ME., Reid, JM., Peng, KW., Jia, L., Russell, SJ., Ames, MM. Tissue distribution of viral gene expression after intravenous administration of an oncolytic measles virus encoding the sodium-iodide symporter (MV-NIS) in transgenic IfnarKO x CD46 Ge mice. Proc. Am. Assoc. Cancer Res. 47: 494, 2006.
 
53.            Coward, L., Gorman, G., Noker, P., Hamilton, A. Sebti, S., Jia, L. A rapid and selective method for the analysis of GGTI-2418 in mouse plasma by HPLC/MS/MS. American Society of Mass Spectrometry (ASMS). May, 2006.
 
54.            Coward, L., Kerstner-Wood, C., Cork, L., Noker, P., Jia, L., Hamilton, A., Sebti, S., Gorman. G.  Analysis of GGTI-2418 in Plasma and its Pharmacokinetics by HPLC/MS/MS.  The AAPS Journal 2006; 8(S2): T2024
 
55.            Kitada S, Jia L, Coward LC, Gorman GS, Noker P, Pellecchia M, and Reed JC .  Bcl-2 antagonist ApoGossypol (NSC736630) displays single-agent activity in Bcl-2 transgenic mice and has superior efficacy and pharmacology with less toxicity compared to Gossypol (NSC19048). Am. Hematology Soc. 2006.
 
56.            P. Noker, R., Fulton, J. Heath, L. Jia, J.M. Reid, M.M. Ames, K.M. Schweikart, and J.E., Tomaszewski. Toxicity and Pharmacokinetics of 1-Methyl-D-Tryptophan in Rats and Dogs. Proc. Am. Assoc. Cancer Res. 48: 366, 2007.
 
57.            J.M., Reid, R.M. McGovern, S.A. Buhrow, L. Jia, J., Tomaszewski, B.J. Jean-Claude, M.M. Ames.  Lead compound selection in a series of combi-molecules with dual EGFR inhibitory and    DNA alkyating activity.  Proc. Am. Assoc. Cancer Res. 48: 937, 2007.
 
58.            Roberts, M.J., Coward, L., Noker, P. Jia, L. In Vitro Bioavailability Testing of GGTI-2418 Using the Caco-2 Model. Proc. 2007 EORTC-ASCO, Belgium. 
 
59.            Greg Gorman, Lori Coward, Corenna Kerstner-Wood, Lea Freeman, Patricia E. Noker, Craig Beattie, Tapas K. Das Gupta, Lee Jia.  Quantitative analysis of Azurin p28, an anti-tumor peptide: Serum stability and mouse pharmacokinetics. Proc. Am. Assoc. Cancer Res. 49: 1138, 2008.
 
60.            Noker, P., Coward, L., Gorman, G., Jia, L. Pharmacokinetics, Tissue Distribution, and Excretion of GGTI-2418, an Inhibitor of Geranylgeranyl Transferase I, in Mice. Proc. Am. Assoc. Cancer Res. 49: 785, 2008.
 
61.            Kitada, S., Wei, J., Kress, C.L. Zhai, C. Krajewska, M., Jia, L., Pellecchia, M., Reed, J.C.  In vitro and in vivo efficacy and toxicity comparison between ApoGossypol and Gossypol, Bcl-2 Antagonists. Proc. Am. Assoc. Cancer Res. 49: 1044, 2008
 
62.            Reid, J.M., McGovern, R.M. Kuffel, M.J., Jia, L., Ames, MM. Species comparison of 1-Methyl-D-tryptophan metabolism by cryopreserved hepatocytes from beagle dog, Fisher rat, CD2F1 mouse and pooled human. Proc. Am. Assoc. Cancer Res. 49: 1137, 2008
 
63.            Malhotra, SV., Kumar, V., Parchment, RE., Jia, L., Noker, PE., Misra, RN., Narayanan VL., Tomaszewski, JE. Ionic Liquid ‘Therapeutic Agents’- New Paradigm in Drug Development.  Am. Chem. Soc. Philadelphia, August 17-21, 2008.
 
64.            Gorman, G., Coward, L., Kerstner-Wood, C., Noker, P., Beattie, C.W., Jia, L. Metabolic Characterization of Azurin p28 in Human, Mouse and Monkey Liver Microsomes.  The AAPS Journal 2008;10(S2): M2230
 
65.            Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Malhotra, S.V. Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. 2009, 48th annual meeting of Society of Toxicology. Abs# 2067
 
66.            Reid, J.M., McGovern, R.M., Buhrow, S.A., Jia, L., Ames, M.M. LC/MS/MS assay and mouse pharmacokinetics and metabolism of the eukaryotic elongation factor-2 kinase inhibitor NSC 745343. Proc. Am. Assoc. Cancer Res. 50: 709, 2009.
 
67.            Gorman, G., Coward, L., Kerstner-Wood, C., Freeman, L., Noker, P.E., Sharifi, N., Figg, W., Jia, L. Pharmacokinetic, Metabolic and Stability Investigations of CCN, a Conjugate of Colchicine and Cyanonilutamide. The AAPS Journal 2009;11(S2): T2234.
 
68.            Rayburn, E., Wang, W., Grau, S., Li, H., Xu, H., Zhang, X., Li, M., Sommers, C., Jia, L., Lee, M. Zhang, R., Enterohepatic circulation of indolecarboxamide ML-970 (NSC 716970), an investigative anticancer agent. Proc. Am. Assoc. Cancer Res. 51: 875, 2010.
 
69.            Reid, JM., Buhrow, SA., Safgren, SL., Jia, L., Schweikart, K., Noker, P., Davis, M., Collins, J., Goetz, MP., Ames. MM. Endoxifen pharmacokinetics and bioavailability in female rats and dogs. Proc. Am. Assoc. Cancer Res. 51: 632, 2010.
 
70.            Buhrow, S.A., Reid, J.M., Walden, C.A., Jia, L., Davis, M., Keefer, L., Barazi, H., Ames, MM. Pharmacokinetics, metabolism and tissue distribution of the nitric oxide-donating prodrug JS-K following administration in liposomes. Proc. Am. Assoc. Cancer Res. 51: 646, 2010.
 
71.            Gorman, G.S., Noker, P.E., Coward, L.U., Ross, D, Guertin, P.A., Jia, L. In-vitro and In-vivo Drug-Drug Interaction Studies with SPINALON, a combination of buspirone and levodopa/ carbidopa for spinal cord injury. The AAPS Journal 2010; 12(S2):T2405.
 
72.            J. Meng, Y. Wang, L. Jia, X-J. Liang. Epigenetic Characteristics of Endohedral Metallofullerene Nanoparticles with anti-tumor activity and low toxicity The AAPS Journal 2010; 12(S2): W4444.
 
73.            M. Song, S. Zhang, T. Hang, L. Jia. Panax notoginseng saponins in dogs determined by LC/MS/MS following oral administration of Danshen Tablets. The AAPS Journal 2010; 12(S2): W4477.
 
74.            Malhotra, S.V., Kumar, V., Parchment, R.E., Jia, L. Noker, P.E., Kumar, K., Misra, R.N., Narayanan, V.L., Tomaszewski, J.E., Cytotoxicity studies of ionic liquids for potential anticancer drug therapy. The AAPS Journal 2010; 12(S2): T3010.
 
75.            Xue, J., Shao, J, Dai, Y, Liu, H., Chen, NS., Huang, JL., Jia,* L Overview of Global Development of Photodynamic Therapy for Cancer and China’s First Generation of Photosensitizer ZnPcS2P2 in Clinical Trials. 17th International Biophysics Congress (IUPAB), Beijing. 10/30 -11/3, 2011.
 
76.            Shao, JW., Dai, YC., Xue, JP., Jia, L. Anticancer activity and mechanism of ZnPc in human hepatocellular carcinoma cell line HepG2. The AAPS Journal 2011; 12(S2): W4057; Submission ID: AM-11-00707; Wed. Oct. 26; 8:00-12:00 pm.
 
77.            Xue, JP., Fang, Y., Jia, L. Liu, H., Chen, N., Hang, J. Preparation and in vitro photodynamic activities of a novel mono(8-quinolinoxy) phthalocyanato zinc(II). The AAPS Journal 2011; 12(S2): W4078; Submission ID: AM-11-01735; Wed. Oct. 26; 8:00-12:00 pm
 
78.            Shao, JW., Du, H., Bai, Z., Xie, J., Cheng, X., Jia, L. Effects of fermentation conditions on the growth of Cordyceps kyushuensis in submerged culture and its antioxidative and anticancer activity in vitro. The AAPS Journal 2011; 12(S2): T2015; Submission ID: AM-11-01127; Tuesday, October 25, 8:00-12:00 pm
 
79.            Gao, Y., Wang, A., Jia, L. (invited presentation) A urgent need for bilateral acceptability of GLP inspections and regulations between USA and China (制药业的全球化趋势急待中美GLP互认的双边协定). 高银燕,王爱平,贾力,制药业的全球化趋势急待中美GLP互认的双边协定,2011年中国药学大会暨第11届中国药师周论文集, pp 1017-1025, 2011. Nov. 6, 2011. 8:30-12:00 am.
 
80.            Wang, J., Shao, J., Zhang, F., Jia, L. Design, synthesis and anticancer activity of a series of ursolic acid derivatives conjugated to folate: targeting folate receptors on cancer cells. October 14–17, 2012; Chicago. Poster T3023..
 
81.            Fang, Y., Song, J., Wang, M., Zhang, J., Wang, X., Sun, JJ., Jia, L. A novel analytical method for detection of H2O2 by using electrogenerated chemiluminescence of cadmium germanate nanomaterials to overcome interferences from other coreactants: long-term stability and quality analysis. Abstract # 2605.
 
82.            Xie, J., Zhao, R., Lu, Y., Wang, J., Gu, S., Jia, L. Re-engineering PAMAM dendrimer for its multivalent binding specifically to colon cancer cells HT29. XianShan Science Conference. Forum on Cancer Nanotechnology and Nanomedicine. 3rd US-China Symposium on Cancer Nanotech & NanoMed. Beijing, Dec., 5-7, 2012.
 
83.            Lu, Y., Yu, T., Liang, H., Xie, J., Wang, J., Xu, J., Shao, J., Jia, L. S-nitrosocaptopril interferes hetero-adhesion between human colon cancer cells HT-29 and vascular endothelial cells. 2013 AAPS annual meeting; AM-13-0574
 
84.            Xie, J., Zhao, R., Gu, S., Shao, J., Lu, Y., Wang, J., Jia, L. Surface-functionalizing modification of nanomaterial dendrimer PAMAM with anti-epithelial cell adhesion molecule antibody for its binding to colon cancer cells HT29. 2013 National Biotechnology Conference, San Diego, USA
 
85.            J. C. Wang, Y. L. Wan, Y. W. Zhu, Y. S. Lu, J. J. Xie, T. Yu, J. Z. Chen, L. Jia Synthesis, characterization and anti-adhesion effect of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486 (mifepristone) 2013 AAPS annual meeting,AM-13-0927; San Antonio, USA
 
86.            Jingjing Xie, Rongli Zhao, Songen Gu, Jichuang Wang, Yuanfang Li, Haiyan Liang, Ting Yu, Lee Jia Capture behaviors of PAMAM dendrimers functionalized with anti-Sialyl Lewis X antibody in vitro。AM-13-2174, 2013 AAPS annual meeting, San Antonio, USA
 
87.            Wang, Jichuang et al. Effects of metapristone on smooth muscle contraction in isolated rat organs. AM-13-1771. 2013 AAPS annual meeting, San Antonio, USA
 
88.            Chen, J., Wang, J. Jia L. A novel UPLC/MS/MS method and its application to pharmacokinetic determination of metapristone, a novel cancer metastasis chemopreventive agent derived from RU486: pharmacokinetic difference between genders。Abstract AM-13-1044, 2013 AAPS annual meeting, San Antonio, USA
 
 
 
 
 
上一篇: Suhong Yu
下一篇: Jingwei Shao